Match Document Document Title
5349055 Nerve growth factor having altered receptor binding specificities  
A method of altering the receptor binding properties and the stability of neurotrophic factors is set forth. Mutant neurotrophic factors having altered receptor binding specificities are...
5348940 Cyclohexapeptidyl hydroxypropionitrile compounds  
Certain propionitrile compounds which have a cyclohexapeptidyl nucleus and which are found to have antibiotic activity with physical properties suitable for use in therapeutic compositions are...
5349051 Modified interluekin-1β  
The present invention relates to modified forms of IL-1β with altered IL-1β activity. The modified IL-1β is the result of mutations which affect amino acids in the beta barrel portion of the IL-1β...
5349053 Chimeric ligand/immunoglobulin molecules and their uses  
Chimeric molecules having a ligand component linked to an immunoglobulin constant region component are provided for various diagnostic, therapeutic and other uses. These immunoligands can exhibit...
5349058 Nucleic acid encoding human mevalonate kinase  
Nucleic acid sequences, particularly DNA sequences, coding for all or a portion of human mevalonate kinase, expression vectors containing the DNA sequences, host cells containing the expression...
5344774 Human intracisternal A-type retroviral particles associated with sjogren's syndrome  
The present invention relates to purified preparations of a novel retrovirus, to methods of diagnosis and treatment of Sjogren's syndrome, novel cell lines, and model systems for the study of...
RE34705 Nucleotidic sequence coding the surface antigen of the hepatitis B virus, vector containing said nucleotidic sequence, process allowing the obtention thereof and antigen obtained thereby  
Nucleic acid of reduced size and vector containing said nucleotidic sequence of which DNA codes an immunogenic peptidic sequence capable of inducing the generation of antibodies to the virus of...
5328898 Factor XIIIA fibrin binding fragments  
Fibrin binding peptides disclosed include (a) peptides having the amino acid sequence of a human Blood Coagulation Factor XIIIA fragment (i.e.,...
5328835 Expression of immunologically reactive HIV envelope proteins  
A method for expressing proteins which are immunologically reactive with antibodies to lymphadenopathy-associated virus (LAV), now known as Human Immunodeficiency Virus (HIV), is disclosed. The...
5328988 Interleukin-7  
Mammalian Interleukin-7 proteins (IL-7s), DNAs and expression vectors encoding mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant...
5326558 Megakaryocytopoietic factor  
A novel human megakaryocytopoietic factor capable of stimulating the growth and development of colonies of megakaryocytes is provided, including procedures for its purification and use as a...
5321124 Art (rev) protein of human T-cell leukemia virus  
A gene and gene product that regulates the expression of the capsidal envelope genes of HTLV-III/LAV and that can be used to regulate the expression of heterologous (non-viral) genes as well is...
5320940 Methods and compositions for identifying and characterizing individuals having autoimmune rheumatic diseases  
Diagnostic assays wherein sera from a patient suspected of having an ill defined autoimmune rheumatic disease is reacted with antigens specific to the human immunodeficiency virus (HIV) core...
5319071 Soluble interleukin-1 receptors  
Substantially purified and homogeneous soluble human interleukin-1 receptor (shuIL-1R) proteins, DNA encoding the shuIL-1R proteins and pharmaceutical compositions containing the shuIL-1R proteins...
5317010 Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment  
Analogues of bovine and human parathyroid hormone, wherein twenty-fifth, twenty-six and twenty-seventh positions of the natural hormone, Arg-Lys-Lys- each have been substituted with Ala, Asn, Asp,...
5312902 Dimer of the precursor of HIV-2 envelope glycoprotein  
Four glycoproteins of apparent molecular weights 300,000, 140,000, 125,000, and 36,000 (gp300, gp140, gp125, and gp36) are detectable in human immunodeficiency virus type 2 (HIV-2) infected cells....
5310657 Kinetic assay for endotoxin using limulus amebocyte lysate and chromogenic substrate  
A kinetic assay procedure is provided which permits measurement of endotoxin concentration in the range from 0.005 EU/ml to 50 EU/ml. The assay procedure relies on a single reagent substrate...
5310882 Somatotropins with alterations in the α-helix 3 region  
The present invention relates to somatotropin analogues with amino acid changes in the α-helix 3 regions of said somatotropins, changes in the α-helix 2 regions, combinations thereof plus...
RE34606 Modified enzymes and methods for making same  
A cloned subtilsin gene has been modified at specific sites to cause amino acid substitutions at certain spots in the enzyme. The modified enzyme, preferably produced by Bacillus, is useful in...
5310727 Pharmaceutical compositions for parenteral use containing a calcitonin as the active ingredient  
A freeze-dried pharmaceutical composition for parenteral administration which includes a therapeutically effective amount of a calcitonin, as the active ingredient, and human albumin.The...
5308835 Production of the E. coli LT-B enterotoxin subunit  
Methods and compositions are provided for the cloning and expression of genes coding for the non-toxic subunit of the heat-labile enterotoxin (LT-B) of E. coli. The LT-B thus produced may be...
5304541 Methods using novel chimeric transforming growth factor-β1/β2  
The present invention relates to the production of large quantities of a novel chimeric TGF-β, termed TGF-β1/β2, by eucaryotic host cells transfected with recombinant DNA vectors containing the...
5300629 Bactericidal and/or bacteriostatic peptides isolated from hemolymph of honeybees  
New bactericidal and/or bacteriostatic, thermostable peptides which are isolated from hemolymph of immune honeybees and which are distinct from lysozymes, attacins, cecropins, diptericins and...
5298603 GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use  
Expression of a gene coding for human granulocyte macrophage colony-stimulating factor (CSF) in bacteria results in CSF proteins which are biologically active. Modification of the natural or of a...
5290917 Modified polypeptides of IL-1α  
Novel polypeptides having a modified amino acid sequence of human interleukin 1α polypeptides in which a certain amino acid residue(s) in said amino acid sequence is(are) exchanged for other amino...
5290920 Method of purifying human epidermal growth factor  
Human epidermal growth factor is provided in an ultrapure form characterized by the absence of protein contaminants detectable by capillary electrophoresis analysis. A method for obtaining such...
5288852 Human tumor necrosis factor polypeptides  
A novel cloned DNA encoding a human tumor necrosis factor (TNF), a vector having said DNA inserted thereinto, a host transformed with said vector and a novel human TNF polypeptide, and processes...
5286847 Interleukin-1 muteins, their preparation and method of use to inhibit interleukin-1 activity  
Disclosed are novel muteins of IL-1 compounds which can be used to regulate excess IL-1 produced in various diseases in humans and animals. The IL-1 muteins can be prepared by site-directed...
5279822 Monoclonal antibodies against the 28KD protein of S. mansoni  
A hybridoma is provided which provides a monoclonal antibody of isotope IgG2a, which recognizes a strip corresponding to a peptidic fragment of 8kD, isolated by controlled proteolysis of the 28kD...
5278285 Variant of Kunitz-type inhibitor derived from the α3-chain of human type VI collagen produced by recombinant DNA technology  
Kunitz-type inhibitor derived from the α3-chain of human type VI collagen produced by recombinant DNA technology, variants thereof, process, expression vector and recombinant host therefore and...
5278146 CRF analogs  
Analogs of CRF, which are based upon hCRF, oCRF, sauvagine and alpha-helical CRF, are disclosed that can be administered to achieve a substantial elevation of ACTH, β-endorphin, β-lipotropin,...
5273744 Vaccines for the protection of animals against theileria infection  
This invention relates to the development of a vaccine against Theileria parva, which is a protozoan parasite infecting cattle in Africa. The invention specifically relates to the use of the 67...
5273886 Determination of isoaspartate in proteins  
The invention relates to methods and means for quantitative determination of the isoaspartyl content of polypeptides via selective methylation of their fragments, catalyzed by a protein...
5268359 Human tachykinins and their precursor  
A DNA has the nucleotide sequence shown in FIG. 1. The derived amino acid sequence is also shown in FIG. 1. Novel polypeptides have the amino acid sequence corresponding to amino acids 1 to 126,...
5262521 Isolated atrial peptide-degrading enzyme and novel compounds useful as inhibitors thereof  
A novel atrial peptide-degrading enzyme (ADE) is provided in isolated, purified form. The enzyme has a molecular weight of approximately 160,000 Daltons as measured by gel filtration...
5260189 Synthetic HIV-like peptides their compositions and uses  
Highly immunoreactive regions of gp41 of HIV-1, gp32 of HIV-2 and p24 of HIV-1 were identified using synthetic peptides. Superior immunoassay performance is obtained with these peptides linked to...
5258493 Cyclic peptides for treating herpes infections  
Disclosed herein are cyclic peptide derivatives of the formula ##STR1## wherein A is absent or the tripeptide radical ThrGlyAla, R1 is benzyl or benzyl monosubstituted at position 4 of the...
5258492 LHRH analogues with cytotoxic moieties at the sixth position  
The present invention deals with LHRH analogues which contain cytotoxic moieties and have influence on the release of gonadotropins from the pituitary gland of mammals, including humans. The...
5256554 Expression of human immunodeficiency virus (HIV) reverse transcriptase  
This invention describes pHRT25, a plasmid containing a modified pol gene of the Human Immunodeficiency Virus Type 1 (HIV-1), formerly HTLV-III, under control of an inducible trp promoter. Methods...
5252464 Process for producing pentapeptides and intermediates for use in the synthesis  
Pentapeptides having the formula H-Asp-Ser-C-Pro-Arg-OH, where Asp, Ser, Pro and Arg may have L- or D-configuration, and C denotes Asp or Asn in L or D configuration, are synthesized by reacting...
5252718 Fibroblast growth factor antagonists  
Antagonists to basic fibroblast growth factor, a 146 amino acid residue polypeptide, are produced. These antagonists are generally between 10 and 45 residues in length and are characterized by...
5252558 Pentapeptide having specific inhibiting effect on epidermal cell proliferation, the salts thereof, pharmaceutical compositions comprising the same and a process for the preparation of the pentapeptide and the pharmaceutical compositions  
The present invention relates to novel pentapeptide of formula Xaa Glu Asp Ser Gly (SEQ ID NO: 1)wherein Xaa is pyro-alpha-aminoadipic acid, having specific inhibiting effect on epidermal cell...
5250421 Method for producing factor VIII:C-type proteins  
An improved method for producing Factor VIII:c-type proteins is disclosed which involves culturing mammalian cells which are capable of expressing the protein. In accordance with this invention...
5250517 Renin inhibiting compounds  
Compounds which are amino acid derivatives and have the formula ##STR1## in which R1 is hydrogen or methyl, R2 is ethyl, propyl or imidazol-4-yl, R3 is isobutyl, cyclohexylmethyl or benzyl, and A...
5248667 Method of treating psoriasis using synthetic peptide compositions  
Peptides previously disclosed as useful for preventing HIV from binding to cell binding sites have now been shown to have thymoleptic qualities and to be useful for tretment of psoriasis in...
5247070 N-terminal muteins of tumor necrosis factor  
A polypeptide which is a tumor necrosis factor polypeptide having an amino acid sequence represented by from the 1st Ser to the 155th Leu as shown by SEQ ID NO:1 in the Sequence Listing, or its...
5244791 Methods of ester hydrolysis  
A novel method for ester hydrolysis catalyzed by enzymes having an oxyanion hole wherein the amide hydrolysis reaction is minimized. Enzymes are selected or alternatively derived by replacement of...
5245010 Polypeptide of herpes simplex virus Vmw 65 protein  
A polypeptide which inhibits the replication of Herpes Simplex Virus and like viruses, which has the amino acid sequence of consecutive amino acids of HSV protein Vmw 65 and comprises the sequence...
5242902 Defensin peptide compositions and methods for their use  
A method for treating cutaneous and corneal wounds as well as certain microbial-related diseases comprises topically applying a defensin peptide to the affected tissue. The compositions comprise a...
5243030 Conjugates of a synthetic peptide for diagnosis and prevention of influenza virus infection  
Macromolecular conjugates of a synthetic polypeptide having influenza virus antigenic properties are disclosed. These conjugates contain a polypeptide corresponding substantially to the 215-235...